{"id":34040,"date":"2024-05-17T08:02:41","date_gmt":"2024-05-17T08:02:41","guid":{"rendered":"https:\/\/zydq.1006ss.com\/?p=34040"},"modified":"2024-05-17T08:02:41","modified_gmt":"2024-05-17T08:02:41","slug":"os%e3%80%81pfs%e3%80%81dfs%e3%80%81orr%e3%80%81dcr%e3%80%81dor%e3%80%81ttr%e3%80%81ttp%e3%80%81rfs%e3%80%81ddc%e3%80%81cbr%e3%80%81ttf%e4%bb%a3%e8%a1%a8%e4%bb%80%e4%b9%88%e6%84%8f%e4%b9%89","status":"publish","type":"post","link":"http:\/\/zydq.1006ss.com\/?p=34040","title":{"rendered":"OS\u3001PFS\u3001DFS\u3001ORR\u3001DCR\u3001DoR\u3001TTR\u3001TTP\u3001RFS\u3001DDC\u3001CBR\u3001TTF\u4ee3\u8868\u4ec0\u4e48\u610f\u4e49"},"content":{"rendered":"<p>                                        OS\uff1a\u603b\u751f\u5b58\u671f Overall<br \/>\nSurvival\u6307\u7684\u662f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u60a3\u8005\u4ece\u968f\u673a\u5316\u5206\u7ec4\uff08\u6216\u5355\u81c2\u8bd5\u9a8c\u4e2d\u6cbb\u7597\u5f00\u59cb\uff09\u81f3\u56e0\u4efb\u4f55\u539f\u56e0\u5f15\u8d77\u7684\u6b7b\u4ea1\u65f6\u95f4\u3002OS\u88ab\u8ba4\u4e3a\u662f\u80bf\u7624\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u6700\u4f73\u7684\u7597\u6548\u7ec8\u70b9\uff0c\u5f53\u60a3\u8005\u7684\u751f\u5b58\u671f\u80fd\u5145\u5206\u8bc4\u4f30\u65f6\uff0c\u5b83\u662f\u9996\u9009\u7ec8\u70b9\u3002\u6700\u5927\u7684\u4f18\u70b9\u662f\u8bb0\u5f55\u65b9\u4fbf\uff0c\u6700\u5927\u7684\u7f3a\u70b9\u662f\u5728\u5927\u578b\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u968f\u8bbf\u65f6\u95f4\u8f83\u957f\u3002\u6240\u4ee5\u4e34\u5e8a\u4e0a\u5e38\u4f7f\u75285\u5e74\u751f\u5b58\u7387\uff0c\u5373\u67d0\u4e00\u79cd\u80bf\u7624\u7ecf\u8fc7\u7efc\u5408\u6cbb\u7597\u540e\uff0c\u751f\u5b58\u671f\u8d85\u8fc75\u5e74\u7684\u60a3\u8005\u6bd4\u4f8b\u3002<\/p>\n<p>\u968f\u673a\u65f6\u95f4\uff1a\u662f\u7b5b\u67e5\u671f\u68c0\u67e5\u5b8c\u6210\u540e\uff0c\u7b26\u5408\u5165\u6392\u6807\u51c6\uff0c\u786e\u5b9a\u53ef\u4ee5\u5165\u7ec4\uff0c\u7136\u540e\u518d\u968f\u673a\u7cfb\u7edf\u5206\u7ec4\u7684\u65f6\u95f4\u3002\u7b7e\u7f72\u77e5\u60c5\u540c\u610f\u4e66\u7684\u65f6\u95f4\u662f\u7b5b\u9009\u5f00\u59cb\u65f6\u95f4\u3002<\/p>\n<p>PFS\uff1a\u65e0\u8fdb\u5c55\u751f\u5b58\u671fProgression-Free<br \/>\nSurvival\u6307\u4ece\u968f\u673a\u5316\u4e34\u5e8a\u8bd5\u9a8c\u5f00\u59cb\u5230\u80bf\u7624\u53d1\u751f\uff08\u4efb\u4f55\u65b9\u9762\uff09\u8fdb\u5c55\u6216\u56e0\u4efb\u4f55\u539f\u56e0\u5bfc\u81f4\u6b7b\u4ea1\u7684\u65f6\u95f4\u3002<\/p>\n<p>\u7b80\u5355\u8bf4\uff0c\u5c31\u662f\u5728\u836f\u7269\u63a7\u5236\u4e0b\u80bf\u7624\u91cd\u65b0\u751f\u957f\u6240\u9700\u8981\u7684\u65f6\u95f4\u3002\u53ea\u8981\u201c\u75be\u75c5\u672a\u8fdb\u5c55\u201d\u6216\u201c\u672a\u6b7b\u4ea1\u201d\uff0c\u90a3\u4e48\u6b64\u6297\u764c\u836f\u5c31\u662f\u4e00\u76f4\u6709\u6548\u7684\u3002<\/p>\n<p>DFS\uff1a\u65e0\u75c5\u751f\u5b58\u671f\/\u65e0\u7624\u751f\u5b58\u671fDisease-Free Survival\u6307\u4ece\u968f\u673a\u5316\u5f00\u59cb\u81f3\u7b2c\u4e00\u6b21\u80bf\u7624\u590d\u53d1\/\u8f6c\u79fb\u6216\u4efb\u4f55\u539f\u56e0\u6b7b\u4ea1\u7684\u65f6\u95f4\uff08\u5931\u8bbf\u60a3\u8005\u4e3a\u6700\u540e\u4e00\u6b21\u968f\u8bbf\u65f6\u95f4\uff1b\u7814\u7a76\u7ed3\u675f\u65f6\u4ecd\u7136\u5b58\u6d3b\u60a3\u8005\uff0c\u4e3a\u968f\u8bbf\u7ed3\u675f\u65e5\uff09\u3002\u8be5\u7ec8\u70b9\u5e38\u7528\u4e8e\u624b\u672f\u6216\u653e\u7597\u540e\u7684\u8f85\u52a9\u6cbb\u7597\u3002\u5f53\u5f88\u5927\u6bd4\u4f8b\u7684\u60a3\u8005\u901a\u8fc7\u5316\u7597\u8fbe\u5230\u5b8c\u5168\u7f13\u89e3 (CR)\u65f6\uff0cDFS\u4e5f\u53ef\u80fd\u662f\u4e00\u4e2a\u91cd\u8981\u7684\u7ec8\u70b9\u3002<\/p>\n<p>\u76ee\u524d\u5bf9DFS\u5b58\u5728\u4e0d\u540c\u5b9a\u4e49\u548c\u89e3\u91ca\uff0c\u4e0d\u540c\u7814\u7a76\u8005\u4e4b\u95f4\u5728\u5224\u65ad\u75be\u75c5\u590d\u53d1\u6216\u8fdb\u5c55\u65f6\u5bb9\u6613\u4ea7\u751f\u504f\u501a\u3002<\/p>\n<p>ORR\uff1a\u5ba2\u89c2\u7f13\u89e3\u7387 Objective Response Rate\u6307\u80bf\u7624\u7f29\u5c0f\u8fbe\u5230\u4e00\u5b9a\u91cf\u5e76\u4e14\u4fdd\u6301\u4e00\u5b9a\u65f6\u95f4\u7684\u75c5\u4eba\u7684\u6bd4\u4f8b\uff0c\u5305\u542b\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u548c\u90e8\u5206\u7f13\u89e3\uff08PR\uff09\u7684\u75c5\u4f8b\u3002<\/p>\n<p>ORR\u5b9a\u4e49\u4e3a\u5728\u6700\u77ed\u65f6\u95f4\u5185\u80bf\u7624\u5927\u5c0f\u51cf\u5c11\u89c4\u5b9a\u91cf\u7684\u60a3\u8005\u6bd4\u4f8b\u3002\u901a\u5e38\uff0cFDA\u5c06ORR\u5b9a\u4e49\u4e3a\u90e8\u5206\u7f13\u89e3(PR)\u548c\u5b8c\u5168\u7f13\u89e3(CR)\u7684\u603b\u548c\uff0c\u5373\u8fbe\u5230PR\u6216CR\u7684\u60a3\u8005\u6bd4\u4f8b\u3002\u5f53\u4ee5\u8fd9\u79cd\u65b9\u5f0f\u5b9a\u4e49\u65f6\uff0cORR\u662f\u836f\u7269\u6297\u80bf\u7624\u6d3b\u6027\u7684\u76f4\u63a5\u6d4b\u91cf\uff0c\u53ef\u4ee5\u5728\u5355\u81c2\u7814\u7a76\u4e2d\u8bc4\u4f30\u3002<\/p>\n<p>DCR\uff1a\u75be\u75c5\u63a7\u5236\u7387 Disease<br \/>\ncontrol rate<\/p>\n<p>\u6307\u80bf\u7624\u7f29\u5c0f\u6216\u7a33\u5b9a\u4e14\u4fdd\u6301\u4e00\u5b9a\u65f6\u95f4\u7684\u75c5\u4eba\u7684\u6bd4\u4f8b\uff0c\u5305\u542b\u5b8c\u5168\u7f13\u89e3complete response\uff08CR\uff09\u3001partial response\u90e8\u5206\u7f13\u89e3\uff08PR\uff09\u548cstable disease\u75be\u75c5\u7a33\u5b9a\uff08SD\uff09\u7684\u75c5\u4f8b\u3002<\/p>\n<p>DoR\uff1a\u7f13\u89e3\u6301\u7eed\u65f6\u95f4During of response<\/p>\n<p>\u6307\u80bf\u7624\u7b2c\u4e00\u6b21\u8bc4\u4f30\u4e3aCR\u6216PR\u5f00\u59cb\u5230\u7b2c\u4e00\u6b21\u8bc4\u4f30\u4e3aPD\u6216\u4efb\u4f55\u539f\u56e0\u6b7b\u4ea1\u7684\u65f6\u95f4\u3002<\/p>\n<p>TTR\uff1a\u81f3\u8d77\u6548\u65f6\u95f4 time to<br \/>\nresponse<\/p>\n<p>\u4ece\u968f\u673a\u5316\u81f3\u8bb0\u5f55\u7684\u9996\u6b21CR\u6216PR\u7684\u65f6\u95f4\u3002<\/p>\n<p>TTP\uff1a\u81f3\u75be\u75c5\u8fdb\u5c55\u65f6\u95f4 time to<br \/>\nprogression\u4ece\u968f\u673a\u5206\u7ec4\u5f00\u59cb\u5230\u7b2c\u4e00\u6b21\u80bf\u7624\u5ba2\u89c2\u8fdb\u5c55\u7684\u65f6\u95f4\u3002\u4e5f\u6709\u660e\u786e\u5b9a\u4e49\u7684\u65f6\u95f4\u95f4\u9694\uff0cTTP was computed as the interval between the date of therapy startuntil the date on which tumour progression was recorded.\u4e0ePFS\u552f\u4e00\u4e0d\u540c\u5728\u4e8ePFS\u5305\u62ec\u6b7b\u4ea1\uff0c\u800cTTP\u4e0d\u5305\u62ec\u6b7b\u4ea1\u3002\u56e0\u6b64PFS\u66f4\u80fd\u9884\u6d4b\u548c\u53cd\u5e94\u4e34\u5e8a\u6536\u76ca\uff0c\u4e0eOS\u4e00\u81f4\u6027\u66f4\u597d\u3002<\/p>\n<p>\u5728\u5bfc\u81f4\u6b7b\u4ea1\u7684\u975e\u80bf\u7624\u539f\u56e0\u591a\u4e8e\u80bf\u7624\u539f\u56e0\u7684\u60c5\u51b5\u4e0b\uff0cTTP\u662f\u4e00\u4e2a\u5408\u9002\u7684\u6307\u6807\u3002<\/p>\n<p>DDC\uff1a\u75be\u75c5\u63a7\u5236\u65f6\u95f4 duration<br \/>\nof disease control<\/p>\n<p>\u6307\u80bf\u7624\u7b2c\u4e00\u6b21\u8bc4\u4f30\u4e3aCR\u3001PR\u6216SD\u5f00\u59cb\u5230\u7b2c\u4e00\u6b21\u8bc4\u4f30\u4e3aPD(Progressive Disease)\u6216\u4efb\u4f55\u539f\u56e0\u6b7b\u4ea1\u7684\u65f6\u95f4\u3002<\/p>\n<p>CBR\uff1a\u4e34\u5e8a\u83b7\u76ca\u7387 Clinical<br \/>\nbenefit rate<\/p>\n<p>\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09+\u90e8\u5206\u7f13\u89e3\uff08PR\uff09+\u75be\u75c5\u7a33\u5b9a\uff08SD\uff09\uff1e6\u4e2a\u6708<\/p>\n<p>TTF\uff1a\u6cbb\u7597\u5931\u8d25\u7684\u65f6\u95f4Time to Treatment Failure<\/p>\n<p>\u6307\u4ece\u968f\u673a\u5316\u5f00\u59cb\u81f3\u6cbb\u7597\u4e2d\u6b62\/\u7ec8\u6b62\u7684\u65f6\u95f4\uff0c\u5305\u62ec\u4efb\u4f55\u4e2d\u6b62\/\u7ec8\u6b62\u539f\u56e0\uff0c\u5982\u75be\u75c5\u8fdb\u5c55\u3001\u6b7b\u4ea1\u3001\u7531\u4e8e\u4e0d\u826f\u4e8b\u4ef6\u9000\u51fa\u3001\u53d7\u8bd5\u8005\u62d2\u7edd\u7ee7\u7eed\u8fdb\u884c\u7814\u7a76\u6216\u8005\u4f7f\u7528\u4e86\u65b0\u6cbb\u7597\u7684\u65f6\u95f4\u3002<\/p>\n<p>\u5bf9\u4e8e\u80bf\u7624\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7ec8\u70b9\uff0cFDA\u6709\u76f8\u5173\u7684\u6307\u5bfc\u539f\u5219\uff08Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics |<br \/>\nFDA\uff09\uff0c\u539f\u5219\u4e2d\u4ecb\u7ecd\u7684\u80bf\u7624\u7ec8\u70b9\u67095\u7c7b\uff1a1.Overall<br \/>\nSurvival\uff08\u603b\u751f\u5b58\u671f\uff09 2.Endpoints<br \/>\nBased on Tumor Assessments\uff08\u57fa\u4e8e\u80bf\u7624\u8bc4\u4f30\u7684\u7ec8\u70b9\uff093.Endpoints<br \/>\nInvolving Symptom Assessment\uff08\u6d89\u53ca\u75c7\u72b6\u8bc4\u4f30\u7684\u7ec8\u70b9\uff094.Blood<br \/>\nor Body Fluid-Based Biomarkers\uff08\u8840\u6db2\u6216\u4f53\u6db2\u751f\u7269\u6807\u5fd7\u7269\uff09<\/p>\n<p>5.Emerging<br \/>\nEndpoints\uff08\u65b0\u5174\u7ec8\u70b9\uff09<\/p>\n<p>Endpoints Based on Tumor<br \/>\nAssessments\uff08\u57fa\u4e8e\u80bf\u7624\u8bc4\u4f30\u7684\u7ec8\u70b9\uff09<\/p>\n<p>\u5728\u8bb8\u591a\u80bf\u7624\u7814\u7a76\u4e2d\uff0c\u5f71\u50cf\u5b66\u8bc4\u4f30\u901a\u5e38\u4f5c\u4e3a\u75be\u75c5\u7684\u76f4\u63a5\u6d4b\u91cf\uff0c\u540c\u65f6\u4e5f\u662f\u4e34\u5e8a\u51b3\u7b56\u7684\u4f9d\u636e\u3002\u5e38\u89c1\u7684\u5f71\u50cf\u5b66\u8bc4\u4f30\u6807\u51c6\uff0c\u5982RECIST v1.1, iRECIST\u7b49\u3002<\/p>\n<\/p>\n<p>recurrence-free survival (RFS)<\/p>\n<p>\u80bf\u7624RFS\u4ee3\u8868\u75c5\u4eba\u5728\u7ecf\u8fc7\u6297\u80bf\u7624\u6cbb\u7597\u540e\uff0c\u83b7\u5f97\u5b8c\u5168\u7f13\u89e3\u65f6\u5230\u51fa\u73b0\u590d\u53d1\u6216\u8005\u968f\u8bbf\u622a\u6b62\u7684\u65f6\u95f4\uff0c\u5e94\u8be5\u8bf4\u80bf\u7624\u7684RFS\u7684\u65f6\u95f4\u662f\u5f88\u591a\u80bf\u7624\u7684\u4e34\u5e8a\u7814\u7a76\u4e2d\u4e00\u4e2a\u7edf\u8ba1\u5b66\u7684\u7ec8\u70b9\u6307\u6807\u3002<\/p>\n<p>time to recurrence (TTR).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>OS\uff1a\u603b\u751f\u5b58\u671f Overall Survival\u6307\u7684\u662f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u60a3\u8005\u4ece\u968f\u673a\u5316\u5206\u7ec4 &hellip; <a href=\"http:\/\/zydq.1006ss.com\/?p=34040\">\u7ee7\u7eed\u9605\u8bfb <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70],"tags":[],"class_list":["post-34040","post","type-post","status-publish","format-standard","hentry","category-70"],"_links":{"self":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts\/34040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34040"}],"version-history":[{"count":0,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts\/34040\/revisions"}],"wp:attachment":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34040"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}